Trevogrumab
Trevogrumab
Trevogrumab (pronounced: treh-vo-groo-mab) is a monoclonal antibody designed for the treatment of osteoporosis and other bone related disorders.
Etymology
The name "Trevogrumab" is derived from the Latin words "trevo" meaning "to turn" and "grumus" meaning "lump", referring to the drug's ability to affect bone growth. The suffix "-mab" is used for monoclonal antibodies.
Usage
Trevogrumab is used in the treatment of osteoporosis, a condition that weakens bones and makes them prone to fractures. It works by inhibiting the activity of a specific protein that breaks down bone, thus helping to increase bone mass and strength.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used in cancer treatment.
- Osteoporosis: A condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones.
- Bone: The hard, rigid form of connective tissue constituting most of the skeleton of vertebrates, composed chiefly of calcium salts.
- Protein: A molecule composed of polymers of amino acids joined together by peptide bonds.
See Also
External links
- Medical encyclopedia article on Trevogrumab
- Wikipedia's article - Trevogrumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski